UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000027016
Receipt number R000030713
Scientific Title Investigation of interindividual factors in cetuximab pharmacokinetics and clinical responses in Japanese head and neck cancer patients using LC-MS/MS method
Date of disclosure of the study information 2017/04/18
Last modified on 2022/10/20 19:04:39

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Investigation of interindividual factors in cetuximab pharmacokinetics and clinical responses in Japanese head and neck cancer patients using LC-MS/MS method

Acronym

Investigation of interindividual factors in cetuximab pharmacokinetics and clinical responses in Japanese head and neck cancer patients using LC-MS/MS method

Scientific Title

Investigation of interindividual factors in cetuximab pharmacokinetics and clinical responses in Japanese head and neck cancer patients using LC-MS/MS method

Scientific Title:Acronym

Investigation of interindividual factors in cetuximab pharmacokinetics and clinical responses in Japanese head and neck cancer patients using LC-MS/MS method

Region

Japan


Condition

Condition

head and neck cancer

Classification by specialty

Gastrointestinal surgery Oto-rhino-laryngology Oral surgery

Classification by malignancy

Malignancy

Genomic information

YES


Objectives

Narrative objectives1

This study evaluates the interindividual variability of serum cetuximab disposition determined by LC-MS/MS and clinical responses to cetuximab by investigating the patient background, concentration of serum proteins related with cetuximab, and genetic variants of antibody receptor transporters.

Basic objectives2

PK,PD

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Serum concentration of cetuximab before dosing on week 4 or later

Key secondary outcomes



Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

1. Patients treated with intravenous cetuximab for head and neck cancer
2. Patients receiving written informed consent

Key exclusion criteria

1. Patients discontinuing intravenous cetuximab
2. Patients who are judged by physicians as inappropriate for study enrollment

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Junichi
Middle name
Last name Kawakami

Organization

Hamamatsu University School of Medicine

Division name

Department of Hospital pharmacy

Zip code

431-3192

Address

1-20-1 Handayama, Hamamatsu

TEL

053-435-2763

Email

pharmacyham-adm@umin.ac.jp


Public contact

Name of contact person

1st name Takafumi
Middle name
Last name Naito

Organization

Hamamatsu University School of Medicine

Division name

Department of Hospital pharmacy

Zip code

431-3192

Address

1-20-1 Handayama, Hamamatsu

TEL

053-435-2763

Homepage URL


Email

pharmacyham-adm@umin.ac.jp


Sponsor or person

Institute

Department of Hospital pharmacy
Hamamatsu University School of Medicine

Institute

Department

Personal name



Funding Source

Organization

Department of Hospital pharmacy
Hamamatsu University School of Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Clinical Research Review Board of Hamamatsu University School of Medicine

Address

1-20-1 Handayama, Hamamatsu 431-3192

Tel

053-435-2111

Email

rinri@hama-med.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2017 Year 04 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Enrolling by invitation

Date of protocol fixation

2016 Year 06 Month 01 Day

Date of IRB


Anticipated trial start date

2016 Year 06 Month 08 Day

Last follow-up date


Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Study design: Observational study
Object recruitment: All patients who visit our hospital and meet the selection criteria from June 2016 to May 2021
Primary outcome: Serum concentration of cetuximab before dosing on week 4 or later
Secondary outcome:
1. Serum concentrations of anti-cetuximab antibody, soluble EGFR, EGF, and immunoglobulins
2. Genetic variants of FcRn and IgG
3. Serum concentrations of inflammatory cytokines, inflammatory proteins, and immune complex
4. Cachexia stage
5. Therapeutic efficacy
6. Adverse effect
7. Laboratory values


Management information

Registered date

2017 Year 04 Month 17 Day

Last modified on

2022 Year 10 Month 20 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000030713


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name